Safety of Ferric Citrate Hydrate in Pregnant Women With Iron Deficiency Anemia, Fetuses, and Newborns: A Real‐World, Observational, Post‐Marketing Surveillance Study
Journal of Obstetrics and Gynaecology Research · 2026-04 · 52 (4)
DOI: 10.1111/jog.70243 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 25.03.2026. Verfasst von Shinichiro Suzuki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Division, Japan Tobacco Inc., Chuo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Ferric Compounds, Anemia, Iron-Deficiency, Pregnancy Complications, Hematologic. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Tobacco Inc., Torii Pharmaceutical Co. Ltd..
Abstract (Originalsprache)
Aim
This post‐marketing surveillance study determined the real‐world use and safety of ferric citrate hydrate (FC) in fetuses and pregnant women with iron deficiency anemia (IDA).
Methods
Pregnant women with IDA were registered centrally and followed prospectively from the first FC administration until the end of pregnancy or at treatment discontinuation. Demographic characteristics, FC administration, and levels of iron‐ and anemia‐related parameters were collected. Newborns were followed for 7 days after birth.
Results
Registration was from October 2021 to March 2023, and 149 women and 129 newborns were included for analysis. The mean (standard deviation; SD) age of the women was 32.1 (5.1) years, and 75.8% were at ≥ 28 weeks of gestational age at the first FC administration. The mean (SD) daily dose of FC was 494.2 (36.3) mg. FC treatment was continued until the end of pregnancy in 53 of 149 women (35.6%). The most frequent reason for the discontinuation of FC (96/149 women, 64.4%) was an improvement in IDA (68/149 women, 45.6%). Adverse drug reactions (ADRs) led to discontinuation in 4 of 149 women (2.7%). In 7 of 149 women (4.7%), 9 ADRs were found, including constipation (3/149, 2.0%), nausea (2/149, 1.3%), abdominal pain upper (1/149, 0.7%), diarrhea (1/149, 0.7%), hand dermatitis (1/149, 0.7%), and fetal death (1/149, 0.7%). No ADRs were found in newborns. Hemoglobin and serum ferritin levels were increased with FC treatment, but no signs of iron overload were reported.
Conclusions
No previously unknown safety concerns were detected in women, fetuses, or newborns by FC treatment during pregnancy. Trial Registration jRCT2031210322
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Division, Japan Tobacco Inc., Chuo-ku, Tokyo, Japan.
- Medical Affairs Department, Torii Pharmaceutical Co. Ltd., Chuo-ku, Tokyo, Japan.
- Pharmacovigilance Department, Torii Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan.
ORCID-Profile: Kyoko Ito, Ryoichi Yamada
Förderung
- Japan Tobacco Inc.
- Torii Pharmaceutical Co. Ltd.
Zitieren
APA
Suzuki, S., Hashimoto, T., Okuda, Y., Ito, K., Ito, S., Shigeta, M., Goto, Y., Horikawa, E., Nishino, N., & Yamada, R. (2026). Safety of Ferric Citrate Hydrate in Pregnant Women With Iron Deficiency Anemia, Fetuses, and Newborns: A Real‐World, Observational, Post‐Marketing Surveillance Study. Journal of Obstetrics and Gynaecology Research, 52(4). https://doi.org/10.1111/jog.70243
Vancouver
Suzuki S, Hashimoto T, Okuda Y, Ito K, Ito S, Shigeta M, et al. Safety of Ferric Citrate Hydrate in Pregnant Women With Iron Deficiency Anemia, Fetuses, and Newborns: A Real‐World, Observational, Post‐Marketing Surveillance Study. Journal of Obstetrics and Gynaecology Research. 2026;52(4). doi:10.1111/jog.70243
BibTeX
@article{Suzuki2026,
author = {Suzuki, Shinichiro and Hashimoto, Teruo and Okuda, Yuri and Ito, Kyoko and Ito, Sayaka and Shigeta, Masahiko and Goto, Yuki and Horikawa, Eiji and Nishino, Noriaki and Yamada, Ryoichi},
title = {Safety of Ferric Citrate Hydrate in Pregnant Women With Iron Deficiency Anemia, Fetuses, and Newborns: A Real‐World, Observational, Post‐Marketing Surveillance Study},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2026},
volume = {52},
number = {4},
doi = {10.1111/jog.70243}
}
EUVIMED